Long-term secretion of therapeutic proteins from genetically modified skeletal muscles

被引:61
作者
Naffakh, N
Pinset, C
Montarras, D
Li, ZL
Paulin, D
Danos, O
Heard, JM
机构
[1] INST PASTEUR,LAB RETROVIRUS & TRANSFERT GENET,CNRS URA 1157,F-75015 PARIS,FRANCE
[2] INST PASTEUR,BIOCHIM LAB,F-75015 PARIS,FRANCE
[3] INST PASTEUR,STN CENT MICROSCOPIE ELECTRON,F-75015 PARIS,FRANCE
关键词
D O I
10.1089/hum.1996.7.1-11
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Protein delivery from genetically modified skeletal muscle has been reported previously. However, a stable and prolonged secretion was obtained in immunocompromised or newborn animals only. To evaluate the clinical relevance of this approach, we have transduced myoblasts from an adult beta-glucuronidase-deficient (MPS VII) mouse with retroviral vectors carrying either the human beta-glucuronidase cDNA or the murine erythropoietin (Epo) cDNA. The cells were then grafted into the tibialis anterior muscle of adult immunocompetent MPS VII recipients. Protein expression was controlled either by ubiquitous or muscle-specific transcriptional regulatory elements. Animals were analyzed over an 8-month period. The in situ detection of beta-glucuronidase activity revealed up to 60% of genetically modified myofibers in the recipient muscles. The human desmin promoter and enhancer showed the highest in vivo expression. Secretion of beta-glucuronidase induced a disappearance of lysosomal storage lesions in the liver and spleen of recipient animals. Delivery of Epo led to a permanent increase of hematocrit values over 3 months. These results showed that the transplantation of genetically modified myoblasts allowed a sustained secretion of recombinant proteins at therapeutic levels in immunocompetent adult mice. They suggest that the approach may be considered for human applications.
引用
收藏
页码:11 / 21
页数:11
相关论文
共 40 条
  • [11] GENE-THERAPY FOR HEMOPHILIA-A - PRODUCTION OF THERAPEUTIC LEVELS OF HUMAN FACTOR-VIII IN-VIVO IN MICE
    DWARKI, VJ
    BELLONI, P
    NIJJAR, T
    SMITH, J
    COUTO, L
    RABIER, M
    CLIFT, S
    BERNS, A
    COHEN, LK
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (04) : 1023 - 1027
  • [12] RETROVIRUS VECTOR-TARGETED INDUCIBLE EXPRESSION OF HUMAN INTERFERON-BETA GENE TO B-CELLS
    ENGELHARDT, JF
    KELLUM, MJ
    BISAT, F
    PITHA, PM
    [J]. VIROLOGY, 1990, 178 (02) : 419 - 428
  • [13] GLASER JH, 1973, J LAB CLIN MED, V82, P969
  • [14] PERSISTENT ERYTHROPOIESIS BY MYOBLAST TRANSFER OF ERYTHROPOIETIN CDNA
    HAMAMORI, Y
    SAMAL, B
    TIAN, J
    KEDES, L
    [J]. HUMAN GENE THERAPY, 1994, 5 (11) : 1349 - 1356
  • [15] PHOSPHOHEXOSYL COMPONENTS OF A LYSOSOMAL ENZYME ARE RECOGNIZED BY PINOCYTOSIS RECEPTORS ON HUMAN FIBROBLASTS
    KAPLAN, A
    ACHORD, DT
    SLY, WS
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1977, 74 (05) : 2026 - 2030
  • [16] LEROYVIARD K, 1991, BLOOD, V78, P1596
  • [17] LI ZL, 1991, J BIOL CHEM, V266, P6562
  • [18] MARECHAL V, 1993, BLOOD, V82, P1358
  • [19] CORRECTION OF LYSOSOMAL STORAGE IN THE LIVER AND SPLEEN OF MPS-VII MICE BY IMPLANTATION OF GENETICALLY-MODIFIED SKIN FIBROBLASTS
    MOULLIER, P
    BOHL, D
    HEARD, JM
    DANOS, O
    [J]. NATURE GENETICS, 1993, 4 (02) : 154 - 159
  • [20] LONG-TERM DELIVERY OF A LYSOSOMAL-ENZYME BY GENETICALLY-MODIFIED FIBROBLASTS IN DOGS
    MOULLIER, P
    BOHL, D
    CARDOSO, J
    HEARD, JM
    DANOS, O
    [J]. NATURE MEDICINE, 1995, 1 (04) : 353 - 357